Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

Vials of the Covid-19 vaccine © SHUTTERSTOCK

The life-threatening condition known as thrombosis with thrombocytopenia syndrome (TTS) has been seen in a very small number of people after receiving the adenovirus-based Johnson & Johnson or Oxford-AstraZeneca vaccines, but the risk between different COVID-19 vaccines compared to one another remained unclear.

In a new study published in the BMJ, DPhil student Xintong Li and an international team of researchers used routinely collected health data from five European countries and the USA to produced risk estimates. They found that people who received a first dose of the Oxford-AstraZeneca vaccine ChAdOx1 had a 30% increased risk of thrombocytopenia versus people who received a first dose of the mRNA-based BioNTech, Pfizer vaccine. Although requiring further study, they also saw an increased risk of TTS from the Johnson & Johnson Ad26.COV2 vaccine.

Xintong said: “To our knowledge this is the first multinational analysis comparing the safety of COVID-19 vaccines to each other, rather than comparing them to no vaccination. At this stage of the pandemic our study offers an answer to the question of ‘what vaccine is safer’, rather than ‘are vaccines safer than no vaccination?’”

This potential risk needs to be put in context, as COVID infection itself leads to increased thrombosis risk, and vaccination has been shown to reduce COVID-related complications including risk of blood clots.

Ed Burn, Senior Researcher in epidemiology and health economics at NDORMS said: “Cases of any type of blood clot after vaccination are extremely rare overall, however even a small increase over time may result in a substantial number of affected patients due to the large numbers of vaccine doses administered worldwide. The observed risks after adenovirus-based vaccines should be considered when planning further immunisation campaigns and future vaccine development.”

The study was funded by European Medicines Agency.

Similar stories

The new Botnar strategy is announced

After a year as the Director of the Botnar Institute for Musculoskeletal Sciences, Professor Jonathan Rees announces a new structure and strategy that will further enhance research and treatment of bone, joint and musculoskeletal conditions.

New global health grant to improve outcomes for patients with hip fracture

Hip fracture patients in Low- and Middle-Income Countries (LMIC) in Asia are set to benefit from a new study that aims to bring best practice programmes to improve quality of life for patients and reduce healthcare costs.

NDORMS welcomes great-granddaughter of former Head of Department

Julia Strubell, great-granddaughter of Professor Josep Trueta, visited NDORMS to find out about his time here and to share her own work with staff and students.

Botnar researchers awarded Fellowships

Arani Vivekanantham has been awarded an NIHR Doctoral Fellowship and a Versus Arthritis Clinical Research Fellowship, and Rachel Kuo was awarded an NIHR Doctoral Research Fellowship.

Better diagnosis and treatment of autoimmune diseases moves a step closer

A study published in Nature outlines a way to find the crucial peptides (protein fragments) that drive autoimmunity, as well as the immune cells that respond to them.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.